| Entry |
|
|---|
| Name |
Ciprofibrate (USAN/INN) |
|---|
| Formula |
C13H14Cl2O3
|
|---|
| Exact mass |
288.032
|
|---|
| Mol weight |
289.1545
|
|---|
| Structure |
|
|---|
| Class |
|
|---|
| Remark |
|
|---|
| Efficacy |
Antihyperlipidemic, Triglyceride synthesis inhibitor, Peroxisome proliferator-activated receptor (PPAR) alpha agonist |
|---|
| Comment |
Clofibrate derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04920 | Adipocytokine signaling pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07222 | Peroxisome proliferator-activated receptor (PPAR) agonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C10 LIPID MODIFYING AGENTS
C10A LIPID MODIFYING AGENTS, PLAIN
C10AB Fibrates
C10AB08 Ciprofibrate
D03521 Ciprofibrate (USAN/INN)
Drug groups [BR:br08330]
Hypolipidemic agent
DG01946 Hypolipidemic agent
DG01733 PPAR alpha agonist
DG01547 Fibrate
D03521 Ciprofibrate
Target-based classification of drugs [BR:br08310]
Nuclear receptors
Thyroid hormone like receptors
Peroxisome proliferator-activated receptor (PPAR)
NR1C1 (PPARA)
D03521 Ciprofibrate (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 18
1 C8x C 13.1600 -16.7300
2 C8y C 13.1600 -18.1300
3 C8x C 14.3500 -18.8300
4 C8x C 15.6100 -18.1300
5 C8y C 15.6100 -16.7300
6 C8x C 14.3500 -16.0300
7 O2a O 16.8000 -16.0300
8 C1d C 17.9900 -16.7300
9 C1y C 11.9700 -18.8300
10 C6a C 19.1800 -16.0300
11 O6a O 20.3700 -16.7300
12 O6a O 19.1800 -14.6300
13 C1a C 16.8000 -17.4300
14 C1a C 19.2500 -17.4300
15 C1z C 10.5700 -18.8300
16 C1x C 11.2700 -20.0200
17 X Cl 9.3547 -18.1349
18 X Cl 9.5861 -19.8260
BOND 19
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 5 7 1
8 7 8 1
9 2 9 1
10 8 10 1
11 10 11 1
12 10 12 2
13 8 13 1
14 8 14 1
15 15 9 1
16 9 16 1
17 16 15 1
18 15 17 1
19 15 18 1
|
|---|
